World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
135
Citations
86090
World Ranking
2030
National Ranking
1152

Michael D. Prados publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Michael D. Prados sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 610 publications — 73rd percentile

73% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Michael D. Prados D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Michael D. Prados sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 135 D-Index — 90th percentile

90% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Michael D. Prados is affiliated with the University of California, San Francisco in the United States. Their research predominantly focuses on Medicine and Biochemistry, Genetics and Molecular Biology, with significant work particularly in Genetics, Molecular Biology, Neurology, Radiology, Nuclear Medicine and Imaging, and Immunology.

The main topics addressed in their research include Glioma Diagnosis and Treatment, Neuroblastoma Research and Treatments, Cancer Genomics and Diagnostics, Immunotherapy and Immune Responses, Radiomics and Machine Learning in Medical Imaging, Brain Metastases and Treatment, and Chromatin Remodeling and Cancer.

Michael D. Prados has contributed to numerous publications across various venues. The most frequent venues for their work are Neuro-Oncology, Journal of Clinical Oncology, bioRxiv (Cold Spring Harbor Laboratory), Neuro-Oncology Advances, and Zenodo (CERN European Organization for Nuclear Research).

Recent papers authored or co-authored by Michael D. Prados include:

  • Association of Maximal Extent of Resection of Contrast-Enhanced and Non-Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed Glioblastoma, 2020, JAMA Oncology
  • Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma, 2023, Journal of Clinical Oncology
  • Response assessment in paediatric high-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group, 2020, The Lancet Oncology
  • Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma, 2020, Journal of Clinical Investigation
  • RNA aggregates harness the danger response for potent cancer immunotherapy, 2024, Cell

Frequently collaborating co-authors in their work include Sabine Mueller, Cassie Kline, Annette M. Molinaro, Adam Resnick, and Javad Nazarian.

Best Publications

  • Comprehensive genomic characterization defines human glioblastoma genes and core pathways

    Roger McLendon;Allan Friedman;Darrell Bigner;Erwin G. Van Meir

  • The Somatic Genomic Landscape of Glioblastoma

    Cameron W. Brennan;Roel G W Verhaak;Aaron McKenna;Benito Campos

  • Oncogenic Signaling Pathways in The Cancer Genome Atlas

    Francisco Sanchez-Vega;Marco Mina;Joshua Armenia;Walid K. Chatila

  • Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

    Henry S. Friedman;Michael D. Prados;Patrick Y. Wen;Tom Mikkelsen

  • Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer.

    Katherine A. Hoadley;Christina Yau;Christina Yau;Toshinori Hinoue;Denise M. Wolf

  • Comprehensive Characterization of Cancer Driver Genes and Mutations.

    Matthew H Bailey;Collin Tokheim;Eduard Porta-Pardo;Sohini Sengupta

  • Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors

    Jeanette E Eckel-Passow;Daniel H Lachance;Annette M. Molinaro;Kyle M. Walsh

  • Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

    Ingo K. Mellinghoff;Maria Y. Wang;Igor Vivanco;Daphne A. Haas-Kogan

  • Role of Extent of Resection in the Long-Term Outcome of Low-Grade Hemispheric Gliomas

    Justin S. Smith;Edward F. Chang;Kathleen R. Lamborn;Susan M. Chang

  • A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

    W K A Yung;R E Albright;J Olson;R Fredericks

  • Genomic and Functional Approaches to Understanding Cancer Aneuploidy

    Alison M. Taylor;Alison M. Taylor;Juliann Shih;Gavin Ha;Gavin Ha;Galen F. Gao

  • Outcomes and Prognostic Factors in Recurrent Glioma Patients Enrolled Onto Phase II Clinical Trials

    Eric T. Wong;Kenneth R. Hess;Mary Jo Gleason;Kurt A. Jaeckle

  • Multicenter Phase II Trial of Temozolomide in Patients With Anaplastic Astrocytoma or Anaplastic Oligoastrocytoma at First Relapse

    W. K.Alfred Yung;Michael D. Prados;Ricardo Yaya-Tur;Steven S. Rosenfeld

  • Pathogenic Germline Variants in 10,389 Adult Cancers

    Kuan-Lin Huang;R Jay Mashl;Yige Wu;Deborah I Ritter

  • A hierarchy of self-renewing tumor-initiating cell types in glioblastoma

    Ruihuan Chen;Merry C. Nishimura;Stephanie M. Bumbaca;Samir Kharbanda

  • Prognostic factors for survival of patients with glioblastoma: Recursive partitioning analysis

    Kathleen R. Lamborn;Susan M. Chang;Michael D. Prados

  • Erratum: Comprehensive Characterization of Cancer Driver Genes and Mutations (ARTICLE (2018) 173(2) (371–385), (S009286741830237X), (10.1016/j.cell.2018.02.060))

    Matthew H. Bailey;Collin Tokheim;Eduard Porta-Pardo;Sohini Sengupta

  • Variants in the CDKN2B and RTEL1 regions are associated with high grade glioma susceptibility

    Margaret Wrensch;Robert B. Jenkins;Jeffrey S. Chang;Ru Fang Yeh

  • Epidermal Growth Factor Receptor, Protein Kinase B/Akt, and Glioma Response to Erlotinib

    Daphne A. Haas-Kogan;Michael D. Prados;Tarik Tihan;David A. Eberhard

  • The somatic genomic landscape of glioblastoma

    Cameron W. Brennan;Roel G. W. Verhaak;Aaron Mckenna;Benito Campos

Frequent Co-Authors

Susan M. Chang
Susan M. Chang University of California, San Francisco
Kathleen R. Lamborn
Kathleen R. Lamborn University of California, San Francisco
Patrick Y. Wen
Patrick Y. Wen Harvard University
Mitchel S. Berger
Mitchel S. Berger University of California, San Francisco
Timothy F. Cloughesy
Timothy F. Cloughesy University of California, Los Angeles
William M. Wara
William M. Wara Kaiser Permanente
W. K. Alfred Yung
W. K. Alfred Yung The University of Texas MD Anderson Cancer Center
David A. Larson
David A. Larson University of California, San Francisco
Joanna J. Phillips
Joanna J. Phillips University of California, San Francisco
Lisa M. DeAngelis
Lisa M. DeAngelis Memorial Sloan Kettering Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

While studying Medicine in the USA is a popular choice, there are alternative pathways and related online degrees that offer flexibility and diverse career options in healthcare. For registered nurses looking to advance their qualifications efficiently, the rn to bsn without clinicals route is a convenient option—allowing busy professionals to earn a bachelor's degree with fewer on-site requirements.

For those seeking advanced roles in nursing leadership or clinical practice, there are accelerated msn to dnp programs and easy dnp programs available online. These programs are designed to be more accessible and time-efficient, often providing a streamlined curriculum for experienced nurses to quickly earn a Doctor of Nursing Practice degree.

If you’re just starting out, accelerated lpn programs offer a fast track into practical nursing, allowing entry into the healthcare workforce with minimal delay. Exploring these pathways can help you find the right fit for your goals, schedule, and education level.

Best Scientists Citing Michael D. Prados

Trending Scientists

Recently Published Articles